ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HEMO Hemogenyx Pharmaceuticals Plc

1.646
0.017 (1.04%)
Last Updated: 08:01:20
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.017 1.04% 1.646 1.622 1.698 1.70 1.646 1.70 636,931 08:01:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.98M -0.0035 -4.66 18.61M
Hemogenyx Pharmaceuticals Plc is listed in the Finance Services sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 1.63p. Over the last year, Hemogenyx Pharmaceuticals shares have traded in a share price range of 1.125p to 6.30p.

Hemogenyx Pharmaceuticals currently has 1,141,999,321 shares in issue. The market capitalisation of Hemogenyx Pharmaceuticals is £18.61 million. Hemogenyx Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.66.

Hemogenyx Pharmaceuticals Share Discussion Threads

Showing 1051 to 1074 of 13400 messages
Chat Pages: Latest  44  43  42  41  40  39  38  37  36  35  34  33  Older
DateSubjectAuthorDiscuss
26/1/2020
14:46
sadly every good share it seems has a troll-he just has the fear of missing out syndrome.i v much doubt anyone takes him seriously,hes clearly unstable.
purple11
25/1/2020
15:32
I see he is aggrevating everyone on another thread.
He must know that Hemogenyx will not be funding a Phase one
trial, I am assuming he is not that thick.
So he is being deliberately obtuse and is reveling in the
attention he is receiving.
If he was ignored he might eventually vanish.

nextlink
23/1/2020
12:03
So how many years away to people think phase 1 trials could be?

How much will hemo need to fundraise to get funding for it, it's very expensive.

davevt
22/1/2020
23:15
Purple,

Tweet from HEMO!

hxxps://t.co/ailP7qYX9E?amp=1

marie1980
21/1/2020
20:20
think globalco and your peanut brain may be half way there.....
runwaypaul
21/1/2020
19:14
It's just hilarious!
davevt
21/1/2020
15:40
fair play old boy.just need to get into phase1 trials and this target starts to become a reality. gl
purple11
21/1/2020
15:39
£150m cap or buyout.
on target
21/1/2020
15:32
that's being pedantic!

how long are you holding for?

purple11
21/1/2020
15:30
Spot the difference:

ALL
AML

on target
21/1/2020
15:24
lion 12 months or so.2p 3p its allthe same to me I want to see the price when theyre testing in monkeys and phase 1.it will be nowhere near here.gl
purple11
21/1/2020
15:02
30th May 2019
7:00 am
RNS
Hemogenyx Pharma Plc - CDX Antibody is Effective against ALL in vitro
5th Jun 2019
8:15 am
RNS
Hemogenyx Pharma Plc - CDX Antibody is Effective against AML in vivo

purple11
21/1/2020
15:00
yes it was bottomcat.
purple11
21/1/2020
14:55
No it wasnt purple,...you are such a muppett
johntopdog
21/1/2020
14:50
So how long do you intend holding purple11 to see a healthy profit? I was assured that SXX was a sure thing 18 months ago but fortunately only dipped my toes in and got out quick.
lionheart69uk1
21/1/2020
14:07
last yr it was only a week or so after announcing cdx worked in vitro that they then announced it worked in vivo so an update on car t could come very quickly.
purple11
21/1/2020
13:55
one of the first successes with car t therapy
purple11
21/1/2020
13:46
this is how weve come.the inflection point is just round the corner now imo

scaramouche1941
15 Jan '20 - 21:03 - 3485 of 3486
0 1 0
As far as I know a normal progression in the drug development is 1. Target identification, 2. Target validation, 3. Molecule (antibody discovery, cell construction etc)design, 4. in vitro efficacy, 5. in vivo efficacy, 6. IND-enabling studies, 7. IND, 8. Clinical trials
It looks like Hemo went to IND enabling studies with their antibody and now they are repeating the same with CAR T.

purple11
21/1/2020
13:25
and I recently called the bottom here and heavily brought it so who cares what ppl think of me.i like the stock and believe it will be around a 40m cap company by the time it moves into phase 1 trials.which will be happening soon,probably this year.

the price in the meantime is irrelevant to me unless I want to buy more as im not selling any at the moment,im buying.

we all play our own game and I believe this has multibagger potential which is virtually impossible to buy on the market anywhere else at the moment.so I hold.one rns will put all these piddly trades to bed and ill make my money.the stock is so illiquid as we have recently seen,that when it comes the gains will be large.its along way up to a 40m cap.

why does that mean my opinion is a scam?

purple11
21/1/2020
13:16
thanks a lot.i tried to make a thread where anyone could post,holders or not.i just don't want davet constantly slating the stock on my thread.MOST NORMAL PPL WHO DONT LIKE A STOCK SIMPLY MOVE TO ANOTHER THEY LIKE NOT CONSTANTLY TRY AND SLATE ANYONES OPINION BUT HIS OWN.

THIS IS NOT A BIASED SCAM THREAD ITS A NORMAL THREAD. Christ!

purple11
21/1/2020
13:11
Purple, no wants to read your biased, self moderated, scam thread unfortunately

Well I am happy to read this scam thread.
It would be great if all sensible posters used this thread.
However we do appear stuck with three threads currently.

nextlink
19/1/2020
13:35
look at the numbers on this car-t phase 1 collaboration today, incl. €45m upfront, to put it into context hemo has a current mcap of 8m
purple11
19/1/2020
13:29
interesting post,the big gains lie ahead.

scaramouche1941
15 Jan '20 - 21:03 - 3485 of 3486
0 1 0
As far as I know a normal progression in the drug development is 1. Target identification, 2. Target validation, 3. Molecule (antibody discovery, cell construction etc)design, 4. in vitro efficacy, 5. in vivo efficacy, 6. IND-enabling studies, 7. IND, 8. Clinical trials
It looks like Hemo went to IND enabling studies with their antibody and now they are repeating the same with CAR T.
I am impressed! All this for the money they raised when listed two years ago?!? This is crazy

purple11
19/1/2020
13:25
its great that there is more than one globalco collaborating with HEMO as it gives HEMO far better negotiating power going and a far greater chance of a great deal going forward.all super exciting now imo.
purple11
Chat Pages: Latest  44  43  42  41  40  39  38  37  36  35  34  33  Older

Your Recent History

Delayed Upgrade Clock